Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial

Limited information is available on the clinical course of patients with severe asthma following discontinuation of biologic treatment. Therefore, a post hoc analysis was conducted in patients with severe eosinophilic asthma who participated in the COSMOS trial, where patients received mepolizumab f...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortega, Hector, Lemiere, Catherine, Llanos, Jean-Pierre, Forshag, Mark, Price, Robert, Albers, Frank, Yancey, Steven, Castro, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558891/
https://www.ncbi.nlm.nih.gov/pubmed/31198427
http://dx.doi.org/10.1186/s13223-019-0348-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558891/
https://www.ncbi.nlm.nih.gov/pubmed/31198427
http://dx.doi.org/10.1186/s13223-019-0348-z

Ejemplares similares